| 6.51 -0.05 (-0.76%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.28  |
1-year : | 10.47 |
| Resists | First : | 7.95 |
Second : | 8.97 |
| Pivot price | 7.62 |
|||
| Supports | First : | 6.3 |
Second : | 5.24 |
| MAs | MA(5) : | 6.78 |
MA(20) : | 7.44 |
| MA(100) : | 8.27 |
MA(250) : | 8.21  |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 6.8 |
D(3) : | 11.9 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 13.68 | Low : | 4.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALGS ] has closed above bottom band by 11.0%. Bollinger Bands are 13.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.86 - 6.89 | 6.89 - 6.92 |
| Low: | 6.21 - 6.25 | 6.25 - 6.29 |
| Close: | 6.43 - 6.5 | 6.5 - 6.56 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Thu, 23 Apr 2026
Aligos Therapeutics jumps on China licensing agreement - MSN
Wed, 22 Apr 2026
Aligos (ALGS) Stock: Why Margin Improvement (Institutional Demand) 2026-04-22 - High Reward Trade - Cổng thông tin điện tử tỉnh Lào Cai
Wed, 22 Apr 2026
Aligos (ALGS) Stock: Why Margin Improvement (Institutional Demand) 2026-04-22 - Short Term Trading - Cổng thông tin điện tử tỉnh Tây Ninh
Tue, 21 Apr 2026
Aligos Therapeutics (NASDAQ: ALGS) signs Hep B deal with up to $420M milestones - Stock Titan
Fri, 17 Apr 2026
This drugmaker was about to run out of cash, but a Chinese partner came to the rescue - The Business Journals
Fri, 17 Apr 2026
Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.64e+006 (%) |
| Held by Institutions | 10.3 (%) |
| Shares Short | 290 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.706e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -12 % |
| Return on Assets (ttm) | 907.6 % |
| Return on Equity (ttm) | -69.4 % |
| Qtrly Rev. Growth | 2.19e+006 % |
| Gross Profit (p.s.) | -27.91 |
| Sales Per Share | -75.16 |
| EBITDA (p.s.) | -2.56756e+007 |
| Qtrly Earnings Growth | -2.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -83 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 1.96 |
| Dividend | 0 |
| Forward Dividend | 306180 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|